Beritasulsel.com

Mengabarkan Sesuai Fakta

Penulis: Heri

’Mandiri Benih’ Diinisiasi Gubernur Andi Sudirman, Petani Bulukumba: Kualitasnya Bagus, Benih Mulai Tumbuh

RAGAM

Dapat Bantuan Kapal, Nelayan di Bulukumba: Terima Kasih Pak Gubernur Andi Sudirman, Kami Bisa Tingkatkan Hasil Melaut

RAGAM

Ucapkan Belasungkawa, Gubernur Sulsel Berziarah ke Makam Istri KH Djamaluddin Amien

RAGAM
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis LONDON, UK - EQS Newswire - 10 June 2022 - Financial information from over 100 multinational drug companies, involving over 70,000 data points, have been accumulated over the past 35 years to create a pharmaceutical database. All our data (sales, COGS, SG&A, R&D and other income) have been derived from annual reports, regulatory filings and company presentations, and then analysed, wherever possible, in a like-for-like manner, irrespective of how each company presents the data. This is a key differentiator to competitive products and is important because all company management teams report "adjusted", "core", or "non-GAAP" earnings to show themselves in the best possible light. However, different inclusion/exclusion criteria in the generation of these adjustments lead to distortions and variability. Although some of the companies are multi-divisional, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique because it analyses the individual cost components of each company over time and generates pharma industry weighted averages, allowing peer and industry comparisons to be made. It also generates individual company and industry-wide underlying operating profit (EBIT), both pre-R&D and post R&D. Historically, data from over 100 companies has been accumulated, but industry consolidation means that just 40 are included currently, which command an estimated 76% of the global drug industry. The main exceptions are the Chinese companies where insufficient data are available on a consistent basis. Current companies included in dataset: Click here to find out more: https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/ Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis

World
Ketua HNSI Sebut Penganiayaan Nelayan di Rajuni Tindakan Biadab Tidak Manusiawi

Ketua HNSI Sebut Penganiayaan Nelayan di Rajuni Tindakan Biadab Tidak Manusiawi

BREAKING NEWS

Danyon Brimob Parepare Hadiri Apel Gelar Pasukan Operasi Patuh 2022

RAGAM

Wali Kota Parepare Kunjungi Rumah Suporter PSM yang Meninggal Dunia

RAGAM

Hadiri Apel Gelar Pasukan Operasi Patuh 2022, Pangerang Rahim Apresiasi Kinerja Polres Parepare

RAGAM

Andi Razak Wawo Dorong Taufan Pawe Maju sebagai Calon Gubernur Sulawesi Selatan

RAGAM

Lewat Talkshow, Erna Rasyid Taufan Bahas Pentingnya Pencegahan Pernikahan Dini

RAGAM

Sinergitas DPRD Parepare bersama PAM Tirta Karajae Penuhi Kebutuhan Air Bersih Warga Lumpue

RAGAM
Ngeri! Oknum Polisi Aniaya Nelayan di Rajuni Selayar, Kepala dan Leher Luka Menganga

Ngeri! Oknum Polisi Aniaya Nelayan di Rajuni Selayar, Kepala dan Leher Luka Menganga

Selayar

Angin Puting Beliung Landa Takalar, Gubernur Andi Sudirman Instruksikan Bantuan ke Pulau Tanakeke

RAGAM

Di Bulukumba, Gubernur Andi Sudirman Tinjau Sawah yang Tanam ‘Mandiri Benih’ di Lahan Pertanian Warga

RAGAM

Warga Keluhkan Benih Gratis yang Tidak Tumbuh, Dinas TPHBun Sulsel Pastikan Bukan Program Mandiri Benih

RAGAM
Sudah ditampilkan semua
Tutup